Anti-inflammatory

KPV: what the research actually shows

by JoyBoy 7 min read Published April 17, 2026 No human trials FDA Category 2

Educational content only. Not medical advice. KPV is not FDA-approved for human use. Always consult a qualified healthcare provider.

30-second summary

What it isA three-amino-acid fragment of alpha-MSH (lysine-proline-valine). A tripeptide. Proposed anti-inflammatory.

EvidenceNo human trialsZero published clinical trials, case reports, or case series in humans.

FDA statusNot approved. On the FDA Category 2 interim bulk substances list. Under PCAC review July 23, 2026 for wound healing and inflammatory conditions.

Human dataNone. All existing evidence is rodent colitis models, cell culture, and chemistry stability work.

My bottom line

KPV is an interesting mouse-colitis candidate with no human footprint yet. The “pouchitis” angle people cite online does not have a trial behind it.

Regulatory update · April 17, 2026 KPV is one of seven peptides the FDA Pharmacy Compounding Advisory Committee will review on July 23, 2026 for the 503A bulk drug substances list, specifically for wound healing and inflammatory conditions. Docket FDA-2025-N-6895. Advisory only. Full breakdown.

Why I looked What it is Research Safety FDA & legal Source safety My take Ask your doctor What to do next

Why I looked into this

KPV shows up in biohacking discussions as a gentle anti-inflammatory, usually for gut issues, sometimes for skin. The appeal is obvious: three amino acids, plausible mechanism (alpha-MSH pathway without the pigmentation), and a growing preclinical record. I wanted to know whether any of it has been tested in humans.

It has not. That is the whole story, and that is why this monograph is shorter than most.

TakeawayInteresting mouse biology. Zero human evidence. The gap between the two has not been crossed yet.

What KPV actually is

KPV is the carboxy-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH): lysine, proline, valine. Alpha-MSH is a known regulator of pigmentation and inflammation. The hypothesis behind KPV is that the tripeptide keeps the anti-inflammatory activity without triggering the pigmentation effects.

In cell and rodent work, KPV appears to enter cells, translocate to the nucleus, and inhibit NF-kB and inflammatory cytokine signaling. Whether any of that generalizes to humans is, right now, a question without an answer.

What the human research shows

Question 01

Do published human trials exist?

No. A PubMed search in April 2026 for KPV with “clinical trial” or “human” returns zero results describing KPV administered to human subjects. The few results that return are nanoparticle-delivery reviews and chemistry stability papers. A PubMed search for KPV plus pouchitis returns zero results.

Question 02

What evidence actually exists?

The entire literature is preclinical or chemistry:

Dalmasso et al. 2008, Gastroenterology 134(1):166-78. KPV in a mouse DSS colitis model. Foundational preclinical paper, not human.
Xiao et al. 2017, Molecular Therapy 25(7):1628-1640. KPV-loaded nanoparticles in mouse ulcerative colitis model. Not human.
Laroui et al. 2010, Gastroenterology 138(3):843-53. Drug-loaded nanoparticles in mouse colitis. Not human.
Pawar et al. 2015, Biomed Chromatogr. HPLC stability assay in skin homogenates ex-vivo. Not a clinical trial.

Question 03

What the research does not show in humans

Not shown in humans for ulcerative colitis, Crohn’s disease, or pouchitis
Not shown in humans for topical wound healing
Not shown in humans for any skin condition
No published human pharmacokinetics for oral, topical, or injected KPV
No published human safety data at any dose

About the animal studiesThe mouse colitis data is reproducible within its own paradigm. Mouse colitis and human inflammatory bowel disease are related but not the same biological situation. Claims of efficacy in humans require human trials, and those have not been run.

Known safety signals in humans

No human safety data. No human pharmacokinetic data. Community anecdotes exist but are uncontrolled.

Immunogenicity of synthetic peptides is a real concern that has not been evaluated. Contaminant risk from gray-market sources is its own concern, independent of the peptide itself.

TakeawayNo trials means no safety record. That applies to short-term tolerability and long-term risk equally.

FDA and legal status in the US

FDA approval

None.

503A compounding

Not permitted. Category 2 interim list. Under PCAC review July 2026.

Legal to possess

Gray zone. Distribution for human use is not legal.

WADA status

Not listed. Not a performance-enhancement target.

The July 23 PCAC review will consider KPV for wound healing and inflammatory conditions. Either a favorable or unfavorable vote is possible.

TakeawayKPV is not legitimately available today. The regulatory status may shift after the vote, but the evidence base does not shift with it.

How to evaluate a source: the safety framework

I do not name vendors. I do not link to sellers. The goal is harm reduction, not facilitation.

Green flags

✓ Licensed 503A compounding pharmacy
✓ Third-party certificate of analysis
✓ Requires a valid prescription
✓ US-based with verifiable address
✓ Transparent about identity verification

Red flags

✗ Anonymous crypto-only payment
✗ “Research use only” labeling loophole
✗ No COA or in-house testing only
✗ No physical address
✗ Sells Category 2 substances for human use

The wrinkle for KPV specifically

KPV is a tripeptide, which makes it chemically simple to synthesize but also easy to contaminate or mis-identify. The risk of a source selling the wrong peptide is non-trivial, and there is no human pharmacology to fall back on if something goes wrong.

Cost reality

Short peptides are cheap to make at research grade, which creates a steep temptation for sources to undercut compliance costs. The checklist exists to separate quality from price theater.

Questions worth asking any source

Is the pharmacy 503A-licensed? Can they provide a COA? What identity verification do they perform? A source that cannot answer those questions is not a source.

TakeawayUnder current rules, no KPV source passes. The checklist is still the right lens to read the situation through.

My honest take

Opinion, not evidence

This section is opinion. I have not used KPV. Everything above this line is sourced from the published record. Everything below is my personal perspective.

KPV is the peptide where the gap between “mechanistically sensible” and “actually tested in humans” is the widest on the current list. It has a clean story on paper and no human evidence to validate the story.

A three-amino-acid fragment of alpha-MSH is a plausible-sounding anti-inflammatory. Plausible is not proven.

If I had inflammatory bowel disease and was hoping KPV would help, I would start by asking my gastroenterologist what the approved options are. Mesalamine, biologics, and newer small-molecule inhibitors have actual trials behind them. KPV does not, yet.

I do not take KPV and I am not planning to. The combination of zero human trials, uncertain source identity, and the existence of approved alternatives for IBD makes this the easiest “not yet” in the current FDA review cohort.

If the July vote goes favorably, the regulatory door opens. The evidence door is still closed.

If a real Phase 1 trial happens, the picture could change quickly. Tripeptides are simple molecules, and trial costs are lower than for a complex biologic. Until a trial exists, the mechanistic story is a hypothesis.

Questions to ask your doctor

If you have an inflammatory condition and you are considering KPV, these are the questions I would bring to a clinician.

Given that no published human trials of KPV exist, what is your view on trying it for my situation?
What are the FDA-approved options for my condition that we have not fully explored yet?
If I proceed despite the evidence gap, what would you want to monitor and how often?
Are there drug interactions you are concerned about with any medications I am taking?
What would change your view on KPV for my specific situation?
What signals would you want me to report if I decided to try it?

What to do next

If you are curious

Read the FDA review article

The July 2026 PCAC meeting will set the regulatory picture for KPV for the foreseeable future.

Open the FDA article →

If you are considering

Download the visit-prep packet

Bring the evidence summary and the six questions into a real conversation with your gastroenterologist.

Get the packet →

If you have decided

Work through the 503A checklist

Evergreen source-safety checklist for any peptide source.

Open the checklist →

Sources

Dalmasso et al. 2008, Gastroenterology 134(1):166-78. KPV in mouse DSS colitis. Preclinical.
Xiao et al. 2017, Mol Ther 25(7):1628-1640. KPV nanoparticles in mouse UC. Preclinical.
Laroui et al. 2010, Gastroenterology 138(3):843-53. Nanoparticle drug delivery in mouse colitis.
Pawar et al. 2015, Biomed Chromatogr 29(5):716-21. HPLC stability assay. Chemistry paper, not a trial.
FDA, Category 2 interim list of bulk drug substances.
Federal Register, April 16, 2026. PCAC meeting notice, docket FDA-2025-N-6895.

All cited efficacy work is rodent or cell-based. PubMed search April 2026 returned zero human trials of KPV in any indication by any route.

Related monographs

Healing peptideno human trials

BPC-157

Same review cycle, same evidence gap, different marketed use.

9 min · JoyBoyRead →

Mitochondrialno human trials

MOTS-c

Interesting basic biology, zero exogenous human trials.

7 min · JoyBoyRead →

Regulatorybreaking

FDA review July 2026

Seven peptides, two days. What the meeting means and what it does not.

6 min · JoyBoyRead →

The Peptide File provides educational content based on published research. This article is not medical advice. The Peptide File does not sell, distribute, or facilitate the purchase of any peptide compound. Always work with a qualified healthcare provider.